Sunday 18 October 2026
Export IMMP’s income statement to Excel — free account
Prima BioMed Ltd
IMMP Healthcare Biotechnology
Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025. Revenue growth for three consecutive years.
3.20
0.01
−0.31%
Follow IMMP
| Older periods | Jun '23 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
— | 0.00% | 0.00% | 0.00% | |
| — | 0.00% | 0.00% | 0.00% | ||
ROIC |
— | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (35.13) | (31.71) | (42.34) | |
Capital Expenditures |
— | (0.07) | (0.07) | (0.13) | |
| Other line items | |||||
Cash ROIC |
— | (24.57%) | (14.63%) | (32.48%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026